Agendia B.V.
IRVINE, California and AMSTERDAM, October 24, 2011 -
Agendia, an innovative molecular diagnostics company, today announced that its supervisory board of directors has appointed David Macdonald as chief executive officer.
BRUSSELS, IRVINE, California, and AMSTERDAM, October 18, 2011 -
The EORTC, BIG, and Agendia, a commercial-stage molecular cancer diagnostics company, today announced the completion of patient registration for the EORTC 10041/BIG3-04 MINDACT (Microarray In Node negative and 1-3 positive lymph node Disease may Avoid Chemotherapy Trial) study.
IRVINE, California and AMSTERDAM, October 3, 2011 -
Agendia, an innovative molecular cancer diagnostics company, today announced that the company successfully completed a recent, routine inspection of its Irvine, California-based laboratories by the US Food and Drug Administration (FDA).
IRVINE, California and AMSTERDAM, September 19, 2011 -
- Peer-Reviewed Article Notes That Multi-Gene Subtyping Profile Provides Deeper Insight Into Breast Cancer
Agendia, an innovative molecular cancer diagnostics company, today announced that a published report highlighting the development and validation of its 80-gene BluePrint breast cancer profile was published online in Breast Cancer Research and Treatment, a peer-reviewed publication.
IRVINE, California and AMSTERDAM, August 10, 2011 -
Panel's Recommendations Reinforce Clinical Value of Tests Such as BluePrint
Agendia, a commercial-stage molecular cancer diagnostics company, today announced that the 12th St.
More News
- Agendia Receives 1.27 Million in Funding from the EU’s Seventh Framework Programme
- Not for Release, Distribution or Publication in Whole or in Part, Directly or Indirectly, Into or in the United States, Australia, Canada, or Japan
- Agendia Announces Colorectal Cancer Collaboration With AstraZeneca and The Netherlands Cancer Institute
- Agendia Hires David Macdonald as Chief Operating Officer, Mark Willig as Executive VP of North American Sales, and Doug Bradley as Vice President of Global Marketing
- Agendia Receives Fifth FDA Clearance for Industry Leading MammaPrint(R) Assay
- Study Once More Underpins the Clinical Value of FDA-cleared Breast Cancer Recurrence Assay
- Second Independent Validation Study of ColoPrint Selected for Oral Presentation and Press Conference at ASCO GI in January 2011
- 178m US Lives Covered by Adding Humana Contract for FDA-Cleared Breast Cancer Test
- Agendia Inaugurates New State-of-the-Art Genomics Laboratory in Irvine
- World Leader in Cancer Diagnostics Joins Nation's Top Safety Agency in Calling for Risk-Based Oversight of Genomic Testing
- Agendia Presents Broad Array of Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO 2010 Annual Meeting
- New Study Demonstrates Patients With High-Risk MammaPrint Profile Benefit From Chemotherapy
- Agendia and Ferrer inCode Expand MammaPrint(R) Distribution Agreement to Latin America
- New Service to Provide Breast Cancer Molecular Subtyping
- 12 Cancer Drugs Tested, 20 Leading U.S. Cancer Centers Involved
- Agendia Receives New York State Laboratory Permit and Laboratory Accreditation by College of American Pathologists
- FDA Broadens Clearance for Agendia's MammaPrint(R)
- Agendia to Present Broad Array of Data at 2009 San Antonio Breast Cancer Symposium
- Medicare Administrator Establishes Reimbursement Coding Policy for Agendia's Breast Cancer Recurrence Test MammaPrint(R)
- Agendia Raises US $23 Million in Series E Financing
- Agendia’s Breast Cancer Recurrence Test MammaPrint Included in International St. Gallen Expert Consensus Recommendations
- Agendia Supports Genentech’s Citizen’s Petition Urging FDA to Hold In-Vitro Diagnostic Tests to One Set of Scientific and Regulatory Standards
- Agendia Opens CLIA-Registered U.S. Genomics Laboratory
- Agendia to Present Multiple Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO Annual Meeting
